LINK TO ONE OF OUR 57 MEMBER ASSOCIATIONS FOR LOCAL SUPPORT, ADVICE AND NEWS

view map
close
  • Finland
  • Norway
  • Sweden
  • Estonia
  • Russian Federation
  • Latvia
  • Denmark
  • Lithuania
  • United Kingdom
  • Netherlands
  • Ireland
  • Poland
  • Germany
  • Belgium
  • Czech Republic
  • Ukraine
  • Slovakia
  • Luxembourg
  • Moldova, Republic of
  • Austria
  • France
  • Switzerland
  • Romania
  • Slovenia
  • Croatia
  • Serbia
  • Bosnia & Herzegovina
  • Bulgaria
  • Italy
  • Macedonia, the Former Yugoslav Republic of
  • Spain
  • Greece
  • Israel

Orphazyme Phase 2 Study of Arimoclomol In Gaucher Disease

24 June 2020

Sharing news from Orphazyme A/S, our CEO Tanya Collin-Histed writes:

“The news is a step forward for Gaucher disease patients and their families. We are excited to hear that there was evidence of arimoclomol’s ability to cross the blood-brain barrier.

Due to the success of ERT, type 3 patients are living longer however the impact of the neurological disease can be debilitating and in some cases fatal. As a community we are grateful to Orphazyme for their commitment in this area of huge unmet need.”

https://www.orphazyme.com/news-feed/2020/6/24/orphazyme-phase-2-study-of-arimoclomol-in-gaucher-disease-demonstrates-marked-improvements-in-key-clinical-markers